US6406867B1
(en)
*
|
1996-08-16 |
2002-06-18 |
Human Genome Sciences, Inc. |
Antibody to human endokine alpha and methods of use
|
US20060099171A1
(en)
*
|
2004-11-05 |
2006-05-11 |
Masahide Tone |
Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
EP1981969A4
(en)
*
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
|
KR100877978B1
(ko)
*
|
2007-01-12 |
2009-01-12 |
가천의과학대학교 산학협력단 |
Cd86 분자가 넉 다운된 형질전환 돼지 혈관 내피세포주 및 이의 제조방법
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
ES2591281T3
(es)
*
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
US20090136446A1
(en)
*
|
2007-11-02 |
2009-05-28 |
Ludwig Institute For Cancer Research Ltd. |
Induction of regulatory t cell-resistant helper cd4+ t cells
|
WO2010030002A1
(ja)
*
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
WO2010040105A2
(en)
|
2008-10-02 |
2010-04-08 |
Trubion Pharmaceuticals, Inc. |
Cd86 antagonist multi-target binding proteins
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
KR101750426B1
(ko)
*
|
2009-09-15 |
2017-06-23 |
씨에스엘 리미티드 |
신경 질환들의 치료
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
US20130122046A1
(en)
*
|
2010-07-09 |
2013-05-16 |
Institut Pasteur Of Shanghai, Cas |
Regulatory factor of foxp3 and regulatory t cells and use thereof
|
US8440195B2
(en)
|
2010-11-12 |
2013-05-14 |
National University Corporation Chiba University |
Inhibition of CD69 for treatment of inflammatory conditions
|
PT2750690T
(pt)
*
|
2011-11-15 |
2019-01-10 |
Walter & Eliza Hall Inst Medical Res |
Mediador solúvel
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
KR20150130283A
(ko)
|
2013-03-15 |
2015-11-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
생체분자 보조제를 갖는 백신
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
CA2929181A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
AU2015236369B2
(en)
|
2014-03-24 |
2017-02-16 |
Novartis Ag |
Monobactam organic compounds for the treatment of bacterial infections
|
IL293603B2
(en)
|
2014-04-07 |
2024-03-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
SG11201610074YA
(en)
|
2014-06-06 |
2016-12-29 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
EP3177593A1
(en)
|
2014-08-06 |
2017-06-14 |
Novartis AG |
Quinolone derivatives as antibacterials
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
JP7084138B2
(ja)
|
2014-08-19 |
2022-06-14 |
ノバルティス アーゲー |
癌処置に使用するための抗cd123キメラ抗原受容体(car)
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
CN107001295B
(zh)
|
2014-12-16 |
2021-02-02 |
诺华股份有限公司 |
作为LpxC抑制剂的异噁唑异羟肟酸化合物
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
KR20170129802A
(ko)
|
2015-03-10 |
2017-11-27 |
아두로 바이오테크, 인코포레이티드 |
"인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
RU2021121771A
(ru)
|
2015-04-08 |
2022-01-12 |
Новартис Аг |
Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
JP6812364B2
(ja)
|
2015-06-03 |
2021-01-13 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌診断用抗gitr抗体
|
JP2018521983A
(ja)
|
2015-07-16 |
2018-08-09 |
バイオカイン セラピューティックス リミテッド |
がんを治療するための組成物および方法
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
CA3007022A1
(en)
*
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
EP3393504A1
(en)
|
2015-12-22 |
2018-10-31 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
WO2017117112A1
(en)
|
2015-12-28 |
2017-07-06 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
CN108473569B
(zh)
|
2016-01-11 |
2022-11-22 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
EA038098B1
(ru)
|
2016-02-19 |
2021-07-06 |
Новартис Аг |
Тетрациклические пиридоновые соединения в качестве противовирусных средств
|
BR112018067679A2
(pt)
|
2016-03-04 |
2019-01-15 |
Novartis Ag |
células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
ES2962269T3
(es)
|
2016-03-24 |
2024-03-18 |
Novartis Ag |
Análogos de nucleósidos alquinil como inhibidores del rinovirus humano
|
KR102495601B1
(ko)
|
2016-06-10 |
2023-02-06 |
리제너론 파마슈티칼스 인코포레이티드 |
항-gitr 항체 및 그것의 사용
|
CA3026356A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017223422A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
WO2018017708A1
(en)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
AU2017308734A1
(en)
|
2016-08-12 |
2019-02-14 |
Janssen Biotech, Inc. |
Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
EP3515475B1
(en)
|
2016-09-21 |
2024-05-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
JOP20190100A1
(ar)
*
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
BR112019011065A2
(pt)
|
2016-12-03 |
2019-10-01 |
Juno Therapeutics Inc |
métodos para determinação da dosagem de células t car
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
US10537637B2
(en)
|
2017-01-05 |
2020-01-21 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
EP3367098A1
(en)
*
|
2017-02-24 |
2018-08-29 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Methods for determining interaction between biological cells
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
EP3606960A1
(en)
|
2017-04-03 |
2020-02-12 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
WO2018213297A1
(en)
|
2017-05-16 |
2018-11-22 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
WO2018223002A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd 123 cd3
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
EP3634584A4
(en)
|
2017-06-09 |
2021-04-07 |
Providence Health & Services - Oregon |
USE OF CD39 AND CD103 FOR THE IDENTIFICATION OF REACTIVE HUMAN TUMOR CELLS FOR THE TREATMENT OF CANCER
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
CA3078270A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
CN111902159A
(zh)
|
2017-11-01 |
2020-11-06 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
JP2021508317A
(ja)
|
2017-12-01 |
2021-03-04 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞の投与および調節のための方法
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3790886A1
(en)
|
2018-05-10 |
2021-03-17 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
EP3801617A1
(en)
|
2018-06-01 |
2021-04-14 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
WO2019241157A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
CA3103629A1
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
BR112020026862A2
(pt)
|
2018-06-29 |
2021-04-20 |
Gensun Biopharma, Inc. |
antagonistas antitumorais de reguladores de pontos de verificação imunológica
|
CN113365663A
(zh)
|
2018-08-30 |
2021-09-07 |
Hcw生物科技公司 |
单链嵌合多肽和其用途
|
US11672826B2
(en)
*
|
2018-08-30 |
2023-06-13 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
WO2020047299A1
(en)
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
CA3109959A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
PE20211605A1
(es)
|
2018-09-07 |
2021-08-23 |
Pfizer |
ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
|
EP3849979A1
(en)
|
2018-09-12 |
2021-07-21 |
Novartis AG |
Antiviral pyridopyrazinedione compounds
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
EP4282416A3
(en)
|
2018-09-29 |
2024-03-06 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CR20210387A
(es)
|
2018-12-20 |
2021-08-19 |
Amgen Inc |
Inhibidores de kif18a
|
JP2022514268A
(ja)
|
2018-12-20 |
2022-02-10 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
SG11202109036WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heteroaryl compounds and uses thereof
|
MX2021010323A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos bicíclicos de heterociclilo y usos de este.
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
RU2734432C1
(ru)
*
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
SG11202112855WA
(en)
|
2019-05-21 |
2021-12-30 |
Amgen Inc |
Solid state forms
|
CN114269903A
(zh)
|
2019-06-21 |
2022-04-01 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
AR120045A1
(es)
|
2019-09-26 |
2022-01-26 |
Novartis Ag |
Compuestos antivirales de pirazolopiridinona
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
CA3160142A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN115873020A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
AU2020381492A1
(en)
|
2019-11-14 |
2022-05-26 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
US11975026B2
(en)
|
2019-11-26 |
2024-05-07 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
EP4087611A1
(en)
|
2020-01-07 |
2022-11-16 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
US20230119606A1
(en)
*
|
2020-02-18 |
2023-04-20 |
Octagon Therapeutics, Inc. |
Immune cell modulators
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
MX2022010910A
(es)
|
2020-03-06 |
2022-10-07 |
Regeneron Pharma |
Anticuerpos anti-gitr y usos de estos.
|
CN111218530B
(zh)
*
|
2020-03-19 |
2023-10-31 |
广西壮族自治区水产科学研究院 |
荧光定量pcr检测十足目虹彩病毒1的引物组及试剂盒
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
JPWO2021225159A1
(no)
*
|
2020-05-08 |
2021-11-11 |
|
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
CN116096906A
(zh)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
|
EP4208261A1
(en)
|
2020-09-03 |
2023-07-12 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
WO2022125497A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
US20240058349A1
(en)
*
|
2020-12-18 |
2024-02-22 |
Northwestern University |
Pi3k inhibitors for protection against glucocorticoid-induced atrophy
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
KR20240004960A
(ko)
|
2021-05-05 |
2024-01-11 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
TW202328090A
(zh)
|
2021-09-08 |
2023-07-16 |
美商雷度納製藥公司 |
Papd5及/或papd7抑制劑
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
CN116925206B
(zh)
*
|
2023-07-18 |
2024-04-23 |
湖南中晟全肽生物科技股份有限公司 |
Gitr相关的多肽及其应用
|